Acute retinal necrosis following dexamethasone intravitreal implant (Ozurdex®) administration in an immunocompetent adult with a history of HSV encephalitis: a case report

Acute retinal necrosis following dexamethasone intravitreal implant (Ozurdex®) administration in an immunocompetent adult with a history of HSV encephalitis: a case report

Abstract Background Dexamethasone intravitreal implants (0.7 mg) (Ozurdex®, Allergan Inc., Madison, NJ) are FDA approved for managing macular oedema (ME) of retinal vein occlusion (RVO). The major complications associated with intravitreal Ozurdex® implant include increased intraocular pressure and...

Full description

Bibliographic Details
Main Authors: Zhi-Yong Zhang, Xiu-Yun Liu, Tao Jiang
Format: Article
Language:English
Published: BMC 2020-06-01
Series:BMC Ophthalmology
Subjects:
Acute retinal necrosis
Intravitreal injections
Dexamethasone intravitreal implant
Retinal vein occlusion
Online Access:http://link.springer.com/article/10.1186/s12886-020-01514-w

Similar Items

Similar Items